Developmental and Epileptic Encephalopathies
Longboard Pharmaceuticals Inc. focuses on developmental and epileptic encephalopathies with studies aimed at seizure control in children and adults affected by severe early-onset epilepsy syndromes. Its research activity in this area centers on conditions marked by frequent motor seizures and substantial neurological impairment.
- Countable motor seizures
- Children and adults with DEE
- Epileptic encephalopathy
The sponsor’s clinical work in this field is directed toward therapeutic options for severe seizure disorders across multiple age groups and international research sites.
Dravet Syndrome
The company also studies Dravet syndrome, a rare and severe epileptic disorder associated with recurrent seizures and complex neurological burden. The sponsored research is centered on seizure reduction in both pediatric and adult populations.
- Seizure burden
- Pediatric and adult patients
- Rare epilepsy
This area of interest reflects a therapeutic emphasis on difficult-to-treat seizure disorders with substantial unmet medical need.
Neurology and Seizure Disorders
Longboard Pharmaceuticals Inc. is active in neurology through programs addressing severe seizure disorders and related central nervous system conditions. Its funded trials are concentrated on clinical outcomes relevant to seizure frequency and disease severity.
- Central nervous system disorders
- Severe epilepsy
- Neurological impairment
The sponsor’s research portfolio is aligned with therapies intended for patients whose epilepsy is associated with significant developmental and functional impact.
